Monday, October 3, 2022


Biotechnology News Magazine

Reversal of Aging of Human Cartilage, Restoring Youthfulness; the First of Its Kind Feat by Edogawa Hospital, Japan

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Cartilage of the knee joint, when severely damaged by age-related wear and tear or injury or osteoarthritis, which is removed and usually discarded, during joint replacement surgery, now could be rejuvenated, becoming a potential source of cells for cell therapy through a disruptive technology that reverses aging, confirmed by Senescence associated ß-Galactosidase, p16, and p21, markers, published in Scientific Reports (, a Nature journal. A conversation between (Late) Prof. Masatoshi Koshiba, (Nobel Laureate, 2002) and Dr. Masahiro Katoh on whether his aging joints could be rejuvenated, inspired orthopedician Dr Shojiro Katoh to develop a path breaking EELS-TALC technique (Enriched with Essentials and Lapped in Scaffold, Transplant-suitable Autologous Leveraged Chondrocytes), making this accomplishment.

Reversal of Aging
Prof. Masatoshi Koshiba (Nobel Laureate; Sitting Rt.) who initiated the idea of restoring youthfulness of cells in the lab with Dr Masahiro Katoh (Sitting Lt; Chairman, Edogawa Hospital), who accomplished Prof. Koshiba’s wishes, helped by Dr Shojiro Katoh (Standing Rt; President, Edogawa Hospital), led team including Dr. Samuel JK Abraham (Standing Lt)

Aging of human body, its organs, tissues and cells is irreversible and in the lab environments, aging is much faster than inside the body. However, EELS-TALC technology has disrupted this conventional belief by making tissues younger, through tissue engineering in a chemically synthesized polymer scaffold, under physical maneuver of orbital shaking in the lab, without genetic manipulation or animal derived products, thus paving way to solutions that, when similar environment is made available inside the body, such reversal of aging might be possible.

EELS TALC cultured chondrocytes have all ideal characteristics, worth recommending as the most suitable in ACI and MACI treatments:

(i) Yielding Hyaline cartilage native to articular joints:

(ii) Hyaluronic acid enrichment, ideal for better healing:

(iii) Enhanced miRNA140, a hall mark of healthy cartilage:

(iv) Chondroprogenitors, mesenchymal stem cells grown from damaged tissues:

(v) Pluripotency marker expression and tissue like growth:

(vi) Increased telomere length, proving youthfulness:
Presented at meetings of British Society of Developmental Biology – Genetics Society & British Society of Gerontology; 2021.

(vii) Lower SA-ß-Gal, p16, p21; confirming the reversal of aging:

(viii) Pre-clinical studies proving, success in vivo:

EELS-TALC method is safe as it does not involve genomic alterations, oncogenes, viruses, or complex growth factors. Now, Dr. Katoh is evaluating ideal transportation of tissues and cells between the hospital and the lab based on earlier reported OPTRACT method ( and additional safety parameters, supported by EELS, JBM Inc, GN Corporation and NCRM, India, before starting clinical studies.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine